Primary sclerosing cholangitis increases the risk for pancreatitis after endoscopic retrograde cholangiopancreatography

Liver International

Volumn 35, Issue 1, 2015, Pages 254-262

  von Seth, Erik ^a,b   Arnelo, Urban ^a,b   Enochsson, Lars ^a,b   Bergquist, Annika ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ERCP; PSC; Adverse events

Indexed keywords

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANNULATION; CHOLANGITIS; CHOLELITHIASIS; CHOLESTASIS; CONTRAST MEDIUM EXTRAVASATION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIMARY SCLEROSING CHOLANGITIS; RISK FACTOR; VERY ELDERLY; ADVERSE EFFECTS; COHORT ANALYSIS; COMPLICATION; PATIENT SELECTION; RISK; SCLEROSING CHOLANGITIS; STATISTICAL MODEL; SWEDEN;

ADULT; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; COHORT STUDIES; HUMANS; LOGISTIC MODELS; ODDS RATIO; PANCREATITIS; PATIENT SELECTION; RISK FACTORS; SWEDEN;

EID: 84921032352     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12640     Document Type: Article

References (27)

1. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-7.
2. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology (Baltimore, Md) 2010; 51: 660-78.
3. Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102: 1781-8.
4. Williams EJ, Taylor S, Fairclough P, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy 2007; 39: 793-801.
5. Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56: 652-6.
6. Cotton PB, Garrow DA, Gallagher J, Romagnuolo J. Risk factors for complications after ERCP: a multivariate analysis of 11 497 procedures over 12 years. Gastrointest Endosc 2009; 70: 80-8.
7. Jeurnink SM, Siersema PD, Steyerberg EW, et al. Predictors of complications after endoscopic retrograde cholangiopancreatography: a prognostic model for early discharge. Surg Endosc 2011; 25: 2892-900.
8. Bangarulingam SY, Gossard AA, Petersen BT, Ott BJ, Lindor KD. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 2009; 104: 855-60.
9. Ismail S, Kylanpaa L, Mustonen H, et al. Risk factors for complications of ERCP in primary sclerosing cholangitis. Endoscopy 2012; 44: 1133-8.
10. Said K, Albiin N, Lindberg B, et al. Pancreatic duct changes are not associated with early signs of chronic pancreatitis at magnetic resonance imaging (MRI) in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2010; 45: 980-6.
11. Enochsson L, Swahn F, Arnelo U, et al. Nationwide, population-based data from 11 074 ERCP procedures from the Swedish Registry for Gallstone Surgery and ERCP. Gastrointest Endosc 2010; 72: 1175-84.
12. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-93.
13. Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP: a prospective study. Gastrointest Endosc 2004; 60: 721-31.
14. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd edn Wiley; New York, Chichester; 2000.
15. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-18.
16. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10.
17. Foutch PG. A prospective assessment of results for needle-knife papillotomy and standard endoscopic sphincterotomy. Gastrointest Endosc 1995; 41: 25-32.
18. Etzel JP, Eng SC, Ko CW, et al. Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointest Endosc 2008; 67: 643-8.
19. Lee JG, Schutz SM, England RE, Leung JW, Cotton PB. Endoscopic therapy of sclerosing cholangitis. Hepatology (Baltimore, Md) 1995; 21: 661-7.
20. van den Hazel SJ, Wolfhagen EH, van Buuren HR, van de Meeberg PC, Van Leeuwen DJ. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy 2000; 32: 779-82.
21. Lindstrom E, Bodemar G, Ryden BO, Ihse I. Pancreatic ductal morphology and exocrine function in primary sclerosing cholangitis. Acta Chirurgica Scandinavica 1990; 156: 451-6.
22. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-34.
23. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-22.
24. Freeman ML. Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007; 5: 1354-65.
25. Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol 2009; 104: 31-40.
26. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (Baltimore, Md) 2011;54:1842-52.
27. European Association for the Study of the L. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.